fiber and semaglutide Oral at a Dose of 25 mg in Adults with Overweight or Obesity oasis-4 semaglutide Oral 25 mg

Rao, A., Steels, E., Beccaria, G., Inder, W

While this 0.01 percentage point gap is small, it reflects different pricing strategies

Rotate sites within the thigh to prevent irritation

"Coupled with the approval to treat adults and pediatric patients aged 12 years and older with obesity, Wegovy is now the GLP-1 with the broadest label." "Adding to the mounting reasons why HCPs choose Wegovy, beyond weight management, the FDA expanded the label in 2024 to include risk reduction of major adverse cardiovascular events (MACE) such as death, heart attack or stroke in adults with known heart disease and with either obesity or overweight." "We continue to explore the real-world potential of Wegovy, and we stand by its beneficial health outcomes beyond weight loss alone."